Main Industry
Health Care
Main Product/Service
1. Ronkyla
2. Ronlytic??
3. RonkylaR Gel
4. RonkylaR Plus
2. Ronlytic??
3. RonkylaR Gel
4. RonkylaR Plus
Founded Year
2018
Unified Business No.
55797608
Status
Active
Number of Employees
0
Total Paid-in
Capital
16,687,500 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
was founded in 2018, aimed to mark breakthroughs, newer, more effective, and safter products.
The initial three products will provide solutions for localized fat reduction in the human body. In addition to the benefits of safety, quality, and convenience, these products are also patented innovative medications. The first product, "Ronkyla Injection" has already received approval from the Taiwan Ministry of Health and Welfare and is successfully on the market.
In the subsequent phase of new product development, the focus will be on further improving the existing products, leading to "Ronkyla Gel" and "Ronkyla Plus" These products aim to achieve better therapeutic effects with fewer side effects, offering healthcare professionals better choices. This allows patients to undergo treatment without undue burden, build self-confidence, and pursue a better quality of life.
The initial three products will provide solutions for localized fat reduction in the human body. In addition to the benefits of safety, quality, and convenience, these products are also patented innovative medications. The first product, "Ronkyla Injection" has already received approval from the Taiwan Ministry of Health and Welfare and is successfully on the market.
In the subsequent phase of new product development, the focus will be on further improving the existing products, leading to "Ronkyla Gel" and "Ronkyla Plus" These products aim to achieve better therapeutic effects with fewer side effects, offering healthcare professionals better choices. This allows patients to undergo treatment without undue burden, build self-confidence, and pursue a better quality of life.
